Polen Focus Growth Sold Its Stake in Boston Scientific (BSX) Over Competition Concerns

1 week ago 6

Soumya Eswaran

Wed, April 29, 2026 astatine 7:37 AM CDT 3 min read

Polen Capital, an concern absorption company, released its “Polen Focus Growth Strategy” first-quarter 2026 capitalist letter. A transcript of the missive tin beryllium downloaded here. The archetypal 4th of 2026 was highly volatile for US equities, driven by AI disruption concerns and the US-Israel struggle successful Iran and the Middle East. In this backdrop, the Polen Focus Growth Strategy declined 17.16% successful the quarter, compared to a -9.78% instrumentality for the Russell 1000 Growth and -4.33% instrumentality for the S&P 500. The Strategy focuses connected mission-critical businesses with recurring gross and competitory advantages and capitalizes connected the volatility to summation investments successful bundle and semiconductor companies. The Strategy remains assured successful the semipermanent imaginable of the Portfolio, emphasizing businesses with beardown economical moats, robust equilibrium sheets, and multi-year net growth. In addition, delight cheque the Strategy’s apical 5 holdings to cognize its champion picks successful 2026.

In its first-quarter 2026 capitalist letter, Polen Focus Growth Strategy highlighted stocks specified arsenic Boston Scientific Corporation (NYSE:BSX). Boston Scientific Corporation (NYSE:BSX) is simply a aesculapian exertion institution that manufactures and markets aesculapian devices for usage successful assorted interventional aesculapian specialties. On April 28, 2026, Boston Scientific Corporation (NYSE:BSX) closed astatine $58.45 per share. One-month instrumentality of Boston Scientific Corporation (NYSE:BSX) was -5.73%, and its shares mislaid 43.18% implicit the past 52 weeks. Boston Scientific Corporation (NYSE:BSX) has a marketplace capitalization of $86.87 billion.

Polen Focus Growth Strategy stated the pursuing regarding Boston Scientific Corporation (NYSE:BSX) successful its Q1 2026 capitalist letter:

"We besides sold Boston Scientific Corporation (NYSE:BSX) implicit concerns astir expanding contention successful its electrophysiology business, which is cardinal to the company's semipermanent maturation profile. While we deliberation their maturation illustration remains coagulated adjacent with the contention and a tenable valuation, we are seeing much compelling opportunities elsewhere and truthful are redeploying that superior to those ideas."

Was Jim Cramer Right About Boston Scientific Corporation (BSX)?

Boston Scientific Corporation (NYSE:BSX) is not connected our database of 40 Most Popular Stocks Among Hedge Funds Heading Into 2026. According to our database, 110 hedge money portfolios held Boston Scientific Corporation (NYSE:BSX) astatine the extremity of the 4th quarter, up from 102 successful the erstwhile quarter. In the archetypal 4th of 2026, Boston Scientific Corporation (NYSE:BSX) delivered consolidated gross of $5.203 cardinal representing a 11.6% year-over-year maturation compared to Q1 2025. While we admit the imaginable of Boston Scientific Corporation (NYSE:BSX) arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you're looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.

Read Entire Article